Nerve News and Research

RSS

Experimental device for obstructive sleep apnea

Obstructive sleep apnea, a dangerous sleep disorder that affects millions of Americans may have found a cure. The disease commonly manifested as snoring but leading to tremendous sleep deprivation can be severely debilitating. Sleep deprivation may lead to car crashes, accidents, high blood pressure, heart attack, stroke, and diabetes.

29 Dec 2010

NEI awards Case Western Reserve $10M for study of retinal diseases

The Departments of Pharmacology and Ophthalmology and Visual Sciences at Case Western Reserve University School of Medicine have been awarded a $10.1 million grant from the National Eye Institute (NEI) to research and develop new treatments for diseases of the retina, a leading cause of blindness.

29 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Male partners' sympathy levels during menstrual periods lacking

New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.

24 Dec 2010

China emerging as world leader in stem-cell R&D

Recent breakthroughs show that China is emerging as a world leader in stem-cell research and development, says Emerging Healthcare Solutions President and CEO Cindy Morrissey.

24 Dec 2010

Jury returns $7M verdict for failure to diagnose and treat cardiac tamponade in bypass surgery patient

A New York State Supreme Court Queens County jury returned a $7,000,000.00 verdict against Patrick Monteleone M.D. and Newell Robinson, M.D. where they failed to diagnose and treat cardiac tamponade (bleeding into the chest) in their patient who underwent cardiac bypass surgery on November 17, 2004.

23 Dec 2010

$Herbal pain medication gets fractured runner back running again$

Herbal pain medication gets fractured runner back running again

Debilitating injuries can impact quality of life long after the injury has occurred and healed, producing long-term pain and limited mobility. Individuals recuperating from a surgery or other procedure may want explore different options to getting back on their feet after an injury.

23 Dec 2010

Later onset of puberty associated with malnutrition, earlier onset to childhood obesity

The timing of the onset of puberty is linked to levels of nutrition: later onset is associated with malnutrition, while earlier onset is linked to childhood obesity. A team of researchers, led by Carol Elias, at the University of Texas Southwestern Medical Center, Dallas, has now generated data in mice that run counter to current thinking about the molecular pathway by which nutrition status affects the onset of puberty. Further, the team defines a new regulatory pathway for the process, which, if confirmed in humans, could potentially lead to new approaches to treating disorders of puberty and fertility.

23 Dec 2010

New cough suppressant from cocoa

People suffering from persistent cough may soon have a remedy that is derived from cocoa. At present researchers are carrying out the final stages of clinical trials of a drug that contains theobromine, an ingredient found in chocolate and cocoa. The drug could be in the market in another two years.

22 Dec 2010

$Emory University study reaffirms benefits of VNS Therapy System for refractory epilepsy$

Emory University study reaffirms benefits of VNS Therapy System for refractory epilepsy

Cyberonics, Inc. announced today that the VNS Therapy System, the only FDA-approved implantable medical device for the treatment of refractory epilepsy, was featured in 22 poster presentations and in the Plenary II session on neurostimulation at the annual American Epilepsy Society Meeting that took place recently in San Antonio, Texas.

22 Dec 2010

New research sheds light on how neurons make connections with one another

Newly published research led by Professor Z. Josh Huang, Ph.D., of Cold Spring Harbor Laboratory sheds important new light on how neurons in the developing brain make connections with one another.

22 Dec 2010

Pepex announces development of combined glucose monitoring and insulin delivery meter

Pepex Biomedical, Inc. has unveiled development of a next generation solution for insulin dependent diabetics which will combine regular glucose monitoring and insulin delivery for diabetes sufferers worldwide. The company is developing a complete product line of multi-function meters which allow simple testing of blood glucose levels and insulin delivery, appropriate to each glucose level measurement, all contained in a single, palm-sized unit. These meters provide anytime, anywhere tracking and treatment of diabetes.

22 Dec 2010

Gilenya offers more benefits for MS therapy than previously realized

In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.

21 Dec 2010

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

21 Dec 2010

Diopsys develops new SD-OCT imaging software for ophthalmologists

Diopsys, today announced the development of software that uses existing Spectral Domain Optical Coherence Tomography images to assist ophthalmologists and optometrists in diagnosing retinal and optic nerve disease such as glaucoma.

21 Dec 2010

Clue to the blues that come with the flu

Vanderbilt University researchers may have found a clue to the blues that can come with the flu - depression may be triggered by the same mechanisms that enable the immune system to respond to infection.

21 Dec 2010

Scientists boost protein supply to enhance muscle function, reduce nerve-dependent fatigue in mice

Researchers at Vanderbilt University have "engineered" a mouse that can run on a treadmill twice as long as a normal mouse by increasing its supply of acetylcholine, the neurotransmitter essential for muscle contraction.

21 Dec 2010

Proteins that unlock the mystery of over 100 brain diseases

An Anglo-American team of researchers have made a medical breakthrough after identifying a large collection of nerve proteins that are involved in around 130 brain diseases including Alzheimer’s and autism.

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development

SEEK, a leading UK privately-owned drug-discovery group, is pleased to announce the establishment of a new joint venture entity with Pernix Therapeutics Holdings, an integrated specialty pharmaceutical company focused primarily on the United States pediatric market.

20 Dec 2010

Nerve News and Research

Experimental device for obstructive sleep apnea

NEI awards Case Western Reserve $10M for study of retinal diseases

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Male partners' sympathy levels during menstrual periods lacking

China emerging as world leader in stem-cell R&D

Jury returns $7M verdict for failure to diagnose and treat cardiac tamponade in bypass surgery patient

Herbal pain medication gets fractured runner back running again

Later onset of puberty associated with malnutrition, earlier onset to childhood obesity

New cough suppressant from cocoa

Emory University study reaffirms benefits of VNS Therapy System for refractory epilepsy

New research sheds light on how neurons make connections with one another

Pepex announces development of combined glucose monitoring and insulin delivery meter

Gilenya offers more benefits for MS therapy than previously realized

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Diopsys develops new SD-OCT imaging software for ophthalmologists

Clue to the blues that come with the flu

Scientists boost protein supply to enhance muscle function, reduce nerve-dependent fatigue in mice

Proteins that unlock the mystery of over 100 brain diseases

Exciting progress made in MS research during 2010

SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News